These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 15868023)

  • 1. Understanding dengue pathogenesis: implications for vaccine design.
    Stephenson JR
    Bull World Health Organ; 2005 Apr; 83(4):308-14. PubMed ID: 15868023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue vaccines approach the finish line.
    Edelman R
    Clin Infect Dis; 2007 Jul; 45 Suppl 1():S56-60. PubMed ID: 17582571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of T cells, cytokines and antibody in dengue fever and dengue haemorrhagic fever.
    Fink J; Gu F; Vasudevan SG
    Rev Med Virol; 2006; 16(4):263-75. PubMed ID: 16791836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternate hypothesis on the pathogenesis of dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in dengue virus infection.
    Noisakran S; Perng GC
    Exp Biol Med (Maywood); 2008 Apr; 233(4):401-8. PubMed ID: 18367628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunopathological mechanisms in dengue and dengue hemorrhagic fever.
    Green S; Rothman A
    Curr Opin Infect Dis; 2006 Oct; 19(5):429-36. PubMed ID: 16940865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dengue hemorrhagic fever with special emphasis on immunopathogenesis.
    Kurane I
    Comp Immunol Microbiol Infect Dis; 2007 Sep; 30(5-6):329-40. PubMed ID: 17645944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathophysiological mechanisms of dengue fever: critical review of current concepts].
    Deparis X; Maréchal V; Matheus S
    Med Trop (Mars); 2009 Aug; 69(4):351-7. PubMed ID: 19725385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dengue vaccine.
    Simasathien S; Watanaveeradej V
    J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S363-77. PubMed ID: 16858980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dengue viral infections.
    Malavige GN; Fernando S; Fernando DJ; Seneviratne SL
    Postgrad Med J; 2004 Oct; 80(948):588-601. PubMed ID: 15466994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Future prospects in developing of dengue vaccines].
    Valero N; Levy A
    Invest Clin; 2008 Jun; 49(2):135-8. PubMed ID: 18717261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dengue vaccines].
    Morita K
    Nihon Rinsho; 2008 Oct; 66(10):1999-2003. PubMed ID: 18939503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.
    Melino S; Paci M
    FEBS J; 2007 Jun; 274(12):2986-3002. PubMed ID: 17509079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.
    Mongkolsapaya J; Dejnirattisai W; Xu XN; Vasanawathana S; Tangthawornchaikul N; Chairunsri A; Sawasdivorn S; Duangchinda T; Dong T; Rowland-Jones S; Yenchitsomanus PT; McMichael A; Malasit P; Screaton G
    Nat Med; 2003 Jul; 9(7):921-7. PubMed ID: 12808447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.
    Guy B; Chanthavanich P; Gimenez S; Sirivichayakul C; Sabchareon A; Begue S; Yoksan S; Luxemburger C; Lang J
    Vaccine; 2004 Sep; 22(27-28):3563-74. PubMed ID: 15315835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue and dengue haemorrhagic fever: implications of host genetics.
    Chaturvedi U; Nagar R; Shrivastava R
    FEMS Immunol Med Microbiol; 2006 Jul; 47(2):155-66. PubMed ID: 16831202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the relationship between antibody-dependent enhancement and immunological distance with application to dengue.
    Adams B; Boots M
    J Theor Biol; 2006 Sep; 242(2):337-46. PubMed ID: 16631802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.